Isavuconazole safe and effective to treat aspergillus infection in patients with cancer
the ONA take:
According to new research presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2014), isavuconazole is as effective as voriconazole for the treatment of aspergillus infection in patients with cancer. In the phase 3 study comparing isavuconazole, new antifungal agent, with voriconazole in patients with uncontrolled cancer, researchers found that the two agents were equally efficacious against the invasive fungal disease.
Furthermore, researchers observed fewer adverse effects associated with isavuconazole versus voriconazole. Compared with those that took voriconzaole, patients who took isavuconazole had less ocular, epidermal, and hepatobiliary toxicity.
Fungal infections caused by aspergillus and other fungi can be particularly harmful in immunocompromised patients undergoing treatment for cancer. These fungal infections often increase morbidity and mortality in these patients, especially those with hematological malignancies like leukemia and lymphoma.
Based on the results of the study, Astellas and Basilea Pharmaceutica International Ltd. have submitted a new drug application to the U.S. Food and Drug Administration (FDA) for isavuconazole for the treatment of invasive aspergillosis and invasive mucormycosis.
Isavuconazole as effective as voriconazole for treatment of aspergillus infection in patients with cancer.
Sign Up for Free e-newsletters
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
- Mindfulness Training May Improve End-of-Life Conversations in Advanced Cancer
- Aligning Patient Goals With End of Life Treatment Decisions
- Study Suggests Greater Focus on the Needs of Family Caregivers of Patients With Cancer
- First Antibody-Based Treatment Regimen Approved for First-Line Treatment of Multiple Myeloma
- Increased Diabetes Risk Associated With Cancer Development
- Childhood Neuroblastoma Survivors at Risk for Psych Impairment
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|